Cancer treatment
The Latest
-
Zandelisib Evaluated As Treatment For Marginal Zone Lymphoma
MEI Pharma and Kyowa Kirin have begun an international phase 2 clinical trial for zandelisib as a potential treatment for marginal zone and follicular lymphomas. 
MEI Pharma and Kyowa Kirin have begun an international phase 2 clinical trial for zandelisib as a potential treatment for marginal zone and follicular lymphomas. -
Genor Biopharma Says It Will Make Cheaper Breast Cancer Drugs Than Competitors
Genor Biopharma's drug will compete with offerings from Swiss biotechnology company Roche and Britain's GSK. 
Genor Biopharma's drug will compete with offerings from Swiss biotechnology company Roche and Britain's GSK. -
Cancer Drug Developed By Chinese Biotech BeiGene Gets Green Light
BeiGene's anti-PD-1 antibody immunotherapy tislelizumab received regulatory approval to treat advanced or metastatic urothelial carcinoma. 
BeiGene's anti-PD-1 antibody immunotherapy tislelizumab received regulatory approval to treat advanced or metastatic urothelial carcinoma. -
InnoCare Pharma Raises $289 Million In Hong Kong IPO Amid Market Downturn
Shares of the Beijing-based cancer drug producer was 300 times oversubscribed amid strong interest from global investors. 
Shares of the Beijing-based cancer drug producer was 300 times oversubscribed amid strong interest from global investors. -
Gilead Sciences To Buy Cancer Treatment Firm Forty Seven In $4.9 Billion Deal
The acquisition will give Gilead access to Forty Seven's lead cancer drug called Magrolimab, which is supposedly able to turn off a tumor cell's CD47 signals. 
The acquisition will give Gilead access to Forty Seven's lead cancer drug called Magrolimab, which is supposedly able to turn off a tumor cell's CD47 signals. -
Merck To Spin-Off Businesses To Focus More On Growth Drivers
Merck & Co will be spinning off its other businesses, including its women's health and biosimilar drug units, into separate publicly-listed companies. 
Merck & Co will be spinning off its other businesses, including its women's health and biosimilar drug units, into separate publicly-listed companies. -
Pfizer To Acquire Cancer Drug Producer Array Biopharma For $10.64 Billion
Pfizer plans to acquire Array Biopharma specifically for its Braftovi and Mektovi drug combination treatments, which has been proven to be effective in treating colorectal cancer. 
Pfizer plans to acquire Array Biopharma specifically for its Braftovi and Mektovi drug combination treatments, which has been proven to be effective in treating colorectal cancer. -
Artificial Intelligence for Cancer Diagnosis, Award-Winning IT Specialist Claims Possible
Another genius aims to create a huge breakthrough in the field of medicine to help people especially those who are suffering cancer and those who will in the future. 
Another genius aims to create a huge breakthrough in the field of medicine to help people especially those who are suffering cancer and those who will in the future. -
Artificial Intelligence for Cancer Diagnosis, Award-Winning IT Specialist Claims Possible
Another genius aims to create a huge breakthrough in the field of medicine to help people especially those who are suffering cancer and those who will in the future. Another genius aims to create a huge breakthrough in the field of medicine to help people especially those who are suffering cancer and those who will in the future.
